http://www.zibb.com/all/theme/cq/Cephalon+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Tue, 24 Nov 2009 19:33:48 GMTTue, 24 Nov 2009 19:33:48 GMT608831http://www.zibb.com/all/theme/cq/Cephalon+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.newratings.com/en/main/company_headline.m?id=1994413NEW YORK, November 24 (newratings.com) - Analysts at Jefferies & Co upgrade Cephalon (ticker: CEPH) from "hold" to "buy." The target price has been raised from $58 to $63. [more]http://www.newratings.com/en/main/company_headline.m?id=1994413Cephalon IncorporatedTue, 24 Nov 2009 19:33:48 GMThttp://www.zibb.com/article/5688192/Cephalon+Shares+Dropped+After+Mixed+Drug+Trial+Results+CEPH11/23/2009 - Cephalon (NASDAQ:CEPH) shares dropped 9% after the company said that the experimental drug CINQUIL did not reduce symptoms of an inflammatory allergy in children any better than a placebo, according to a Bloomberg report. CEO at Ception Therapeutics Steve Tullman said, "We arehttp://www.zibb.com/article/5688192/Cephalon+Shares+Dropped+After+Mixed+Drug+Trial+Results+CEPHCephalon IncorporatedMon, 23 Nov 2009 15:47:49 GMThttp://www.marketwatch.com/story/europe-drug-stocks-rally-cephalon-slides-2009-11-23?siteid=rss&rss=1BOSTON (MarketWatch) -- Drug stocks advanced in early action Monday, boosted by a rally among major European drugmakers, while shares of Cephalon Inc. fell on news that a later-stage clinical study for its pediatric drug Cinquil came up short-handed.http://www.marketwatch.com/story/europe-drug-stocks-rally-cephalon-slides-2009-11-23?siteid=rss&rss=1Cephalon IncorporatedMon, 23 Nov 2009 15:35:00 GMThttp://www.foxbusiness.com/story/markets/industries/health-care/drug-stocks-advance-cephalon-falls-study/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Fhealthcare+%28FOXBusiness.com+-+Industries+-+Health+Care%29Drug Stocks Advance; Cephalon Falls On Studyhttp://www.foxbusiness.com/story/markets/industries/health-care/drug-stocks-advance-cephalon-falls-study/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Fhealthcare+%28FOXBusiness.com+-+Industries+-+Health+Care%29Cephalon IncorporatedMon, 23 Nov 2009 14:52:00 GMThttp://philadelphia.bizjournals.com/philadelphia/stories/2009/11/23/daily1.html?ana=yfcpcCeption Therapeutics Inc. and Cephalon Inc. announced mixed results Monday for late-stage testing of Cinquil, an experimental drug the two suburban Philadelphia biotechnology companies are developing to treat pediatric eosinophilic esophagitis.http://philadelphia.bizjournals.com/philadelphia/stories/2009/11/23/daily1.html?ana=yfcpcCephalon IncorporatedMon, 23 Nov 2009 14:05:16 GMThttp://finance.yahoo.com/news/Ception-Therapeutics-and-prnews-662397563.html?x=0&.v=1MALVERN, Pa. and FRAZER, Pa., Nov. 23 /PRNewswire-FirstCall/ -- Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq: CEPH - News) today announcedhttp://finance.yahoo.com/news/Ception-Therapeutics-and-prnews-662397563.html?x=0&.v=1Cephalon IncorporatedMon, 23 Nov 2009 13:00:00 GMThttp://www.prnewswire.com/news-releases/ception-therapeutics-and-cephalon-provide-initial-results-of-a-phase-iibiii-study-of-cinquil-in-pediatric-eosinophilic-esophagitis-71514007.htmlCeption Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis.http://www.prnewswire.com/news-releases/ception-therapeutics-and-cephalon-provide-initial-results-of-a-phase-iibiii-study-of-cinquil-in-pediatric-eosinophilic-esophagitis-71514007.htmlCephalon IncorporatedMon, 23 Nov 2009 13:00:00 GMThttp://www.cephalon.com//media/news-releases/article/ception-therapeutics-and-cephalon-provide-initial-results-of-a-phase-iibiii-study-of-cinquil-in-ped/MALVERN, Pa. and FRAZER, Pa., Nov. 23 /PRNewswire-FirstCall/ -- Ception Therapeutics, Inc., a...http://www.cephalon.com//media/news-releases/article/ception-therapeutics-and-cephalon-provide-initial-results-of-a-phase-iibiii-study-of-cinquil-in-ped/Cephalon IncorporatedMon, 23 Nov 2009 05:00:00 GMThttp://www.newsvine.com/_news/2009/11/12/3495323-cephalon-barr-settle-fentora-disputeCephalon Inc. will give Barr Pharmaceuticals Inc. a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement, according to a Securities and Exchange Commission filing Thursday.http://www.newsvine.com/_news/2009/11/12/3495323-cephalon-barr-settle-fentora-disputeCephalon IncorporatedThu, 12 Nov 2009 23:07:48 GMThttp://www.thestreet.com/_yahoo/story/10624194/1/bulls-buy-cephalon-webmdoptions-recap.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NABullish traders bet on Cephalon, Smithfield Farms and WebMD.. Check out TheStreet for the latest stock market news and financial investment headlines.http://www.thestreet.com/_yahoo/story/10624194/1/bulls-buy-cephalon-webmdoptions-recap.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NACephalon IncorporatedMon, 09 Nov 2009 21:17:10 GMThttp://seekingalpha.com/article/172053-cephalon-s-upside-and-downside?source=feedSteve Alexander submits:Cephalon (CEPH) specializes in bio-pharmaceuticals that target central nervous system (<ahttp://seekingalpha.com/article/172053-cephalon-s-upside-and-downside?source=feedCephalon IncorporatedSun, 08 Nov 2009 11:35:47 GMThttp://www.istockanalyst.com/article/viewarticle/articleid/3610517Cephalon (CEPH) specializes in bio-pharmaceuticals that target central nervous system (CNS) disorders, pain treatments, and oncology (cancer). The star product over the past few years has been Provigil, a treatment for sleep disorders, that has accounted for about half of sales.http://www.istockanalyst.com/article/viewarticle/articleid/3610517Cephalon IncorporatedThu, 05 Nov 2009 16:56:11 GMThttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=9470FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2009 net sales of $535.2 million, a 9 percent increase compared to net sales of $489.7 million for the third quarter 2008. Basic income per commonhttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=9470Cephalon IncorporatedWed, 28 Oct 2009 01:00:00 GMThttp://news.yahoo.com/s/ap/20091027/ap_on_bi_ge/us_earns_cephalonCephalon Inc. on Tuesday said third-quarter earnings fell from a year ago, when the biotech firm recorded a $66.1 million tax benefit.http://news.yahoo.com/s/ap/20091027/ap_on_bi_ge/us_earns_cephalonCephalon IncorporatedTue, 27 Oct 2009 22:39:11 GMThttp://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/10/26/financial/f100959D09.DTL&feed=rss.businessBiotechnology company Cephalon Inc. said Monday it signed an option deal that could lead to the buyout of privately-held BioAssets Development Corp. Under the deal, Cephalon will pay BioAssets $30 million upfront and an additional payment upon closing of the...http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/10/26/financial/f100959D09.DTL&feed=rss.businessCephalon IncorporatedMon, 26 Oct 2009 17:10:20 GMThttp://www.xconomy.com/boston/2009/10/26/bioassets-inks-30m-acquisition-option-deal/Frazer, PA-based Cephalon (NASDAQ: ]) has agreed to pay $30 million for an option to acquire BioAssets Development Corporation, a Wellesley, MA-based companyhttp://www.xconomy.com/boston/2009/10/26/bioassets-inks-30m-acquisition-option-deal/Cephalon IncorporatedMon, 26 Oct 2009 14:27:16 GMThttp://www.contractpharma.com/news/2009/10/26/cephalon_signs_option_to_acquire_bioassets__Cephalon, Inc. and BioAssets Development Corp. (BDC) have signed an agreement that will provide Cephalon with an option to acquire BDC.http://www.contractpharma.com/news/2009/10/26/cephalon_signs_option_to_acquire_bioassets__Cephalon IncorporatedMon, 26 Oct 2009 14:08:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=160360&full=1Under the terms of the option agreement, Cephalon will pay BDC an upfront payment of $30 million and, assuming exercise of the option, an additional payment on the closing of the acquisition. BDC stockholders could also receive additional future payments related to regulatory and sales milestones.http://www.biospace.com/news_story.aspx?StoryID=160360&full=1Cephalon IncorporatedMon, 26 Oct 2009 12:00:00 GMThttp://www.genengnews.com/news/bnitem.aspx?name=66525950Cephalon is paying $30 million for an option to acquire BioAssets Development (BDC). BDC has a Phase II tumor necrosis factor (TNF) inhibitor for the treatment of sciatica and relahttp://www.genengnews.com/news/bnitem.aspx?name=66525950Cephalon IncorporatedMon, 26 Oct 2009 00:00:00 GMThttp://www.businessweek.com/investor/content/sep2009/pi20090928_251573.htm?campaign_id=yhooShares of Cephalon are down on fears that growth of its sleep disorder drug Provigil is slowing and could be hurt by the early rollout of generics.http://www.businessweek.com/investor/content/sep2009/pi20090928_251573.htm?campaign_id=yhooCephalon IncorporatedTue, 29 Sep 2009 12:08:55 GMThttp://www.pharmaceutical-business-review.com/news/cortex_reports_second_quarter_results_090814Cortex has reported a net loss of $2.7m, or $0.06 per share for the quarter ended June 30, 2009, compared to a net loss of $3.9m, or $0.08 per share for the corresponding prior year period. For the six months ended June 30, 2009, the company reported a net loss of $5.9m, or $0.http://www.pharmaceutical-business-review.com/news/cortex_reports_second_quarter_results_090814Cephalon IncorporatedFri, 14 Aug 2009 00:00:00 GMThttp://www.bizjournals.com/philadelphia/stories/2009/08/10/daily10.html?ana=from_rssCephalon Inc. completed its previously announced $207 million acquisition of all of the outstanding shares of Arana Therapeutics Ltd., an Australian biotechnology company. Arana will now operate as a wholly owned subsidiary of Frazer, Pa.http://www.bizjournals.com/philadelphia/stories/2009/08/10/daily10.html?ana=from_rssCephalon IncorporatedMon, 10 Aug 2009 21:10:23 GMThttp://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/08-10-2009/0005075049&EDATE=FRAZER, Pa., Aug. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of all of the outstanding ordinary shares of Australian biotechnology company, Arana Therapeutics Limited.http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/08-10-2009/0005075049&EDATE=Cephalon IncorporatedMon, 10 Aug 2009 20:00:00 GMThttp://www.forbes.com/feeds/ap/2009/08/04/ap6740209.htmlFRAZER, Pa. -- Biotechnology company Cephalon Inc. raised its full-year profit forecast Tuesday after second-quarter results topped expectations, but predicted a weaker-than-expected third quarter.http://www.forbes.com/feeds/ap/2009/08/04/ap6740209.htmlCephalon IncorporatedTue, 04 Aug 2009 21:48:51 GMThttp://www.reuters.com/article/marketsNews/idUSN0415478820090804* Net Q2 EPS $1.11 * Sales up 11 pct to $539 mln * NEW YORK, Aug 4 (Reuters) - Cephalon Inc reported higher second quarter profit on Tuesday, helped by strong sales of its flagshiphttp://www.reuters.com/article/marketsNews/idUSN0415478820090804Cephalon IncorporatedTue, 04 Aug 2009 20:29:43 GMT